Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LIAN LianBio	$0.06 +10.0%	$0.35	$0.27 ▼ $4.99	$5.94M	0.23	1.04 million shs	39,001 shs
NKGN NKGen Biotech	$0.24 -4.0%	$0.29	$0.10 ▼ $1.36	$11.24M	1.26	1.42 million shs	26,099 shs
PRLD Prelude Therapeutics	$0.81 -1.8%	$0.90	$0.61 ▼ $6.80	$45.45M	1.22	285,591 shs	48,497 shs
SCLX Scilex	$8.86 -4.2%	$5.59	$3.60 ▼ $63.00	$61.59M	1.19	71,405 shs	238,926 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LIAN LianBio	0.00%	-87.11%	-85.53%	-72.50%	-81.67%
NKGN NKGen Biotech	0.00%	-20.03%	-4.00%	+88.24%	-74.36%
PRLD Prelude Therapeutics	0.00%	-1.19%	-6.51%	-0.62%	-87.03%
SCLX Scilex	0.00%	+37.15%	+84.97%	+47.18%	-87.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	0.3257 of 5 stars	0.0	3.0	0.0	0.0	0.0	2.5	0.0
PRLD Prelude Therapeutics	3.6298 of 5 stars	3.5	5.0	0.0	0.0	0.0	3.3	0.6
SCLX Scilex	1.7907 of 5 stars	3.3	3.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LIAN LianBio	0.00	N/A	N/A	N/A
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	3.00	Buy	$4.50	459.01% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	5,035.44% Upside

Current Analyst Ratings Breakdown

Latest NKGN, SCLX, PRLD, and LIAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	($2.68) per share	N/A
PRLD Prelude Therapeutics	$7M	6.49	N/A	N/A	$2.39 per share	0.34
SCLX Scilex	$56.59M	1.09	N/A	N/A	($27.68) per share	-0.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.69	0.00	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)
SCLX Scilex	-$72.81M	-$29.02	0.00	N/A	N/A	-146.93%	N/A	-82.65%	8/12/2025 (Estimated)

Latest NKGN, SCLX, PRLD, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	N/A	SCLX Scilex	-$4.55	N/A	N/A	N/A	$26.25 million	N/A
8/11/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LIAN LianBio	N/A	10.06	10.06
NKGN NKGen Biotech	N/A	0.02	0.02
PRLD Prelude Therapeutics	N/A	5.18	5.18
SCLX Scilex	N/A	0.10	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LIAN LianBio	74.85%
NKGN NKGen Biotech	76.17%
PRLD Prelude Therapeutics	79.72%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
LIAN LianBio	7.59%
NKGN NKGen Biotech	10.36%
PRLD Prelude Therapeutics	63.90%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable
SCLX Scilex	80	6.95 million	6.40 million	Optionable

NKGN, SCLX, PRLD, and LIAN Headlines

Recent News About These Companies

SCLX Scilex Holding Company - Seeking Alpha

July 1, 2025 | seekingalpha.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

April 15, 2025 | globenewswire.com

Scilex announces 1-for-35 reverse stock split

April 12, 2025 | markets.businessinsider.com

D. Boral Capital Downgrades Scilex Holding (SCLX)

April 12, 2025 | msn.com

Scilex downgraded to Hold from Buy at D. Boral Capital

April 11, 2025 | msn.com

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

April 11, 2025 | globenewswire.com

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN, SCLX, PRLD, and LIAN Company Descriptions

LianBio NASDAQ:LIAN

$0.06 +0.01 (+10.00%)

As of 07/18/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

NKGen Biotech NYSE:NKGN

$0.24 -0.01 (-4.00%)

As of 07/18/2025 03:30 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Prelude Therapeutics NASDAQ:PRLD

$0.80 -0.02 (-1.83%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.82 +0.02 (+2.24%)

As of 07/18/2025 06:31 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Scilex NASDAQ:SCLX

$8.86 -0.39 (-4.22%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.76 -0.09 (-1.07%)

As of 07/18/2025 07:59 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time